Literature DB >> 29400703

Comprehensive review of autoantibodies in patients with hyper-IgM syndrome.

Mohamed-Ridha Barbouche1, Qubo Chen2,3, Marco Carbone4, Imen Ben-Mustapha1, Zakera Shums5, Mehdi Trifa6, Federica Malinverno4, Francesca Bernuzzi4, Haiyan Zhang2,4,7, Nourhen Agrebi1, Gary L Norman5, Christopher Chang8, M Eric Gershwin8, Pietro Invernizzi9,10.   

Abstract

Hyper-immunoglobulin M syndrome is an X-linked primary immunodeficiency disease caused by mutations in the CD40 ligand gene. The CD40 ligand has been recently highlighted as playing a key role in the pathogenesis of primary biliary cholangitis. In the present study, we assessed an extensive set of serum autoantibodies in a series of well-defined patients with hyper-immunoglobulin M syndrome. Serum, liver-related and liver-not-related autoantibodies IgG, IgM and IgA were tested by ELISA and standard indirect immunofluorescence in HEp-2 cells in 13 Tunisian patients (8 males and 5 females, aged 1-12 years) with hyper-immunoglobulin M syndrome during 1995-2012 and, as controls, 21 age- and gender-matched blood donors. The level of IgM antibody against MIT3 was significantly higher in patients than in controls (35.8 vs 10.7, P=0.002). Half of the hyperimmunoglobulin M syndrome patients were found to be anti-MIT3 IgM positive vs none of the controls (P<0.0001). Twenty-three percent of patients were found to be anti-sp100 antibody positive vs only 0.05% of controls. By immunofluorescence, 92.3% of patients were MIT3 IgM positive vs none of the controls. In conclusion, the IgM class of anti-MIT3 antibodies was shown to be present by both ELISA and immunofluorescence in most of the patients with hyper-immunoglobulin M syndrome. The presence of the hallmark of primary biliary cholangitis, a disease where the CD40 ligand is a key player, in an immunodeficiency disease caused by mutations in the CD40 ligand gene is very intriguing and opens new scenarios in understanding the immune pathogenesis of primary biliary cholangitis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29400703      PMCID: PMC6079058          DOI: 10.1038/cmi.2017.140

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  30 in total

1.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

Review 2.  Study of patients with Hyper-IgM type IV phenotype who recovered spontaneously during late childhood and review of the literature.

Authors:  Neslihan Edeer Karaca; Anne Durandy; Nesrin Gulez; Guzide Aksu; Necil Kutukculer
Journal:  Eur J Pediatr       Date:  2011-01-28       Impact factor: 3.183

Review 3.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

4.  'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?

Authors:  P Muratori; L Muratori; M E Gershwin; A J Czaja; G Pappas; S MacCariello; A Granito; F Cassani; P Loria; M Lenzi; F B Bianchi
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium.

Authors:  Carlo Selmi; David L Balkwill; Pietro Invernizzi; Aftab A Ansari; Ross L Coppel; Mauro Podda; Patrick S Leung; Thomas P Kenny; Judy Van De Water; Michael H Nantz; Mark J Kurth; M Eric Gershwin
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

Review 6.  Bacteria and human autoimmunity: the case of primary biliary cirrhosis.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

7.  Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency.

Authors:  Pierre Quartier; Jacinta Bustamante; Ozden Sanal; Alessandro Plebani; Marianne Debré; Anne Deville; Jiri Litzman; Jacov Levy; Jean-Paul Fermand; Peter Lane; Gerd Horneff; Guzide Aksu; Isik Yalçin; Graham Davies; Ilhan Tezcan; Furgen Ersoy; Nadia Catalan; Kohsuhe Imai; Alain Fischer; Anne Durandy
Journal:  Clin Immunol       Date:  2004-01       Impact factor: 3.969

8.  Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients.

Authors:  Hanen Ouadani; Imen Ben-Mustapha; Meriem Ben-ali; Leila Ben-khemis; Beya Larguèche; Raoudha Boussoffara; Sonia Maalej; Ilhem Fetni; Saida Hassayoun; Abdelmajid Mahfoudh; Fethi Mellouli; Sadok Yalaoui; Hatem Masmoudi; Mohamed Bejaoui; Mohamed-Ridha Barbouche
Journal:  Immunogenetics       Date:  2015-11-06       Impact factor: 2.846

9.  Activation induced cytidine deaminase mutant (AID-His130Pro) from Hyper IgM 2 patient retained mutagenic activity on SHM artificial substrate.

Authors:  Hanen Ouadani; Imen Ben-Mustapha; Meriem Ben-Ali; Beya Larguèche; Tihana Jovanic; Sylvie Garcia; Benoit Arcangioli; Houda Elloumi-Zghal; Dahmani Fathallah; Mongia Hachicha; Hatem Masmoudi; François Rougeon; Mohamed-Ridha Barbouche
Journal:  Mol Immunol       Date:  2016-10-04       Impact factor: 4.407

10.  CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance.

Authors:  Maxime Hervé; Isabelle Isnardi; Yen-shing Ng; James B Bussel; Hans D Ochs; Charlotte Cunningham-Rundles; Eric Meffre
Journal:  J Exp Med       Date:  2007-06-11       Impact factor: 14.307

View more
  3 in total

1.  X-linked hyper-IgM syndrome complicated with interstitial pneumonia and liver injury: a new mutation locus in the CD40LG gene.

Authors:  Tian-Jiao Wang; Li-Fang Wu; Junguo Chen; Wen Zhu; Hua Wang; Xiao-Lin Liu; Yi-Qun Teng
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

2.  Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis.

Authors:  Francesco Saettini; Grazia Fazio; Daniele Moratto; Marta Galbiati; Nicola Zucchini; Davide Ippolito; Marco Emilio Dinelli; Luisa Imberti; Mario Mauri; Maria Luisa Melzi; Sonia Bonanomi; Alessio Gerussi; Marinella Pinelli; Chiara Barisani; Cristina Bugarin; Marco Chiarini; Mauro Giacomelli; Rocco Piazza; Giovanni Cazzaniga; Pietro Invernizzi; Silvia Clara Giliani; Raffaele Badolato; Andrea Biondi
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

3.  Autoreactive antibodies control blood glucose by regulating insulin homeostasis.

Authors:  Timm Amendt; Gabriele Allies; Antonella Nicolò; Omar El Ayoubi; Marc Young; Tamás Röszer; Corinna S Setz; Klaus Warnatz; Hassan Jumaa
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.